Taurolidine: A Comprehensive Monograph on its Pharmacology, Clinical Efficacy, and Therapeutic Applications

Section 1: Introduction and Chemical Profile

1.1. Overview and Historical Context

Taurolidine is a synthetic small molecule antimicrobial agent derived from the naturally occurring amino acid, taurine.[1] First synthesized in the 1970s, its development marked the introduction of a novel therapeutic agent with a unique mechanism of action distinct from conventional antibiotics.[1] The initial clinical application of taurolidine was as a prophylactic agent for the prevention and treatment of intraperitoneal bacterial infections, particularly in patients with peritonitis, where it was often used as a surgical lavage solution.[1] This early use established its reputation as a potent, broad-spectrum antimicrobial with a favorable safety profile in local applications.

Over the subsequent decades, the clinical utility of taurolidine has evolved significantly. Recognizing its ability to prevent the formation of microbial biofilms and its low propensity for inducing bacterial resistance, its application shifted towards the prevention of catheter-related infections, a major source of morbidity and mortality in patients requiring long-term vascular access.[7] This has become its primary and most well-established therapeutic role, culminating in its approval in various formulations worldwide for use as a catheter lock solution.[1] Concurrently, research beginning in the late 1990s uncovered potent antineoplastic properties, sparking a parallel line of investigation into its potential as a cancer therapeutic.[2] This dual identity—as both an established anti-infective and an investigational anti-cancer agent—makes taurolidine a subject of considerable scientific and clinical interest.

1.2. Nomenclature, Identification, and Structural Classification

The precise identification of a chemical entity is fundamental to scientific discourse. Taurolidine is known by several systematic and common names, and is cataloged under numerous international registry identifiers.

1.2.1. Systematic and Common Names

The compound's formal chemical nomenclature is complex, reflecting its unique structure. Its International Union of Pure and Applied Chemistry (IUPAC) name is 4,4'-methanediylbis(1,2,4-thiadiazinane) 1,1,1',1'-tetraoxide.[11] An alternative IUPAC name, 4-[(1,1-dioxo-1,2,4-thiadiazinan-4-yl)methyl]-1,2,4-thiadiazinane 1,1-dioxide, is also cited.[12] Its formal name is often listed as 4,4'-methylenebis(tetrahydro-1,2H,4-thiadiazine) 1,1,1',1'-tetraoxide.[2] For clinical and regulatory purposes, its designated International Nonproprietary Name (INN) is taurolidine.[11] Commercially and in literature, it is also referred to by the synonyms Taurolin and Tauroline.[12] When formulated in combination with heparin for the U.S. market, it is known by the brand name Defencath®.[12]

1.2.2. Chemical and Registry Identifiers

Taurolidine is uniquely identified by the Chemical Abstracts Service (CAS) Registry Number 19388-87-5.[2] Its primary accession number in the DrugBank database is DB12473.[1] Other identifiers include the external ID W-3100M and various database numbers such as Reaxys Registry Number 550774, PubChem Substance ID 468593050, and MDL Number MFCD00865076, which facilitate its tracking across chemical and pharmacological databases.[1]

1.2.3. Structural Information and Classification

Taurolidine possesses the chemical formula $C_7H_{16}N_4O_4S_2$.[1] Its average molecular weight is approximately 284.35 to 284.4 g/mol, with a precise monoisotopic mass of 284.061297359 Da.[1] Structurally, the molecule consists of two taurinamide rings derived from the amino acid taurine, which are linked by a central methylene bridge.[3] This symmetrical architecture is central to its function. X-ray diffraction studies have revealed that in its crystalline state, the asymmetric unit contains two independent taurolidine molecules that differ only by rotations around certain bonds.[15]

Chemically, taurolidine is classified as a thiadiazinane. This class of organic compounds is characterized by a six-membered saturated heterocycle containing two nitrogen atoms, one sulfur atom, and three carbon atoms.[1] It is also functionally classified as a sulfone due to the presence of the sulfonyl ($SO_2$) groups within each ring.[11] This unique heterocyclic structure underpins its chemical reactivity and biological activity.

1.3. Physicochemical Properties and Formulation Characteristics

The physical and chemical properties of taurolidine dictate its formulation, storage, and behavior in biological systems. It presents as a white to off-white or light yellow crystalline powder that is odorless.[4] It has a defined melting point of 175 °C.[4]

Its solubility profile is an important consideration for its formulation. It is soluble in organic solvents such as dimethylformamide (DMF) and dimethyl sulfoxide (DMSO) at a concentration of 10 mg/ml, but is only sparingly soluble in an aqueous buffer solution like DMSO:PBS (pH 7.2) at a 1:1 ratio, achieving a concentration of only 0.5 mg/ml.[2] Despite this, it is generally described as water-soluble, particularly in the context of its biological activity, which relies on its interaction with aqueous environments.[16]

A defining characteristic of taurolidine is its chemical instability. It is sensitive to light, air, and heat, necessitating specific storage and handling conditions.[4] It is recommended that the solid compound be stored under refrigerated conditions (0-10 °C) and under an inert gas to prevent degradation.[4] This inherent instability is not merely a pharmaceutical challenge but is fundamental to its mechanism of action. In aqueous solutions, taurolidine is unstable and readily breaks down into its biologically active derivatives.[15] This controlled degradation is the key to its therapeutic effect, as the parent molecule serves as a pro-drug, delivering reactive chemical moieties to the target site. This property reframes a characteristic often viewed as a liability—chemical instability—into a core functional attribute of the molecule.

The molecular architecture of taurolidine, with its two taurinamide rings, provides a chemical scaffold that, upon hydrolysis, is capable of releasing multiple reactive methylol groups.[16] This capacity for generating several reactive species from a single parent molecule likely contributes to its non-specific and broad-spectrum activity against a wide array of microbes.[1] The non-specific chemical nature of this interaction, as opposed to a highly specific enzyme-target binding, is a key reason for the observed low potential for the development of microbial resistance, a significant clinical advantage over traditional antibiotics.[8]

Table 1: Physicochemical and Structural Properties of Taurolidine

Property	Description	Source(s)
IUPAC Name	4,4'-methanediylbis(1,2,4-thiadiazinane) 1,1,1',1'-tetraoxide	11
Common Synonyms	Taurolin, Tauroline, Defencath® (with heparin)	12
CAS Number	19388-87-5	2
DrugBank ID	DB12473	1
Chemical Formula	$C_7H_{16}N_4O_4S_2$	1
Average Molecular Weight	284.35 g/mol	1
Monoisotopic Mass	284.061297359 Da	1
SMILES String	O=S1(=O)CCN(CN2CCS(=O)(=O)NC2)CN1	2
Physical Appearance	White to light yellow, odorless crystalline powder	4
Melting Point	175 °C	4
Solubility Profile	Soluble in DMF (10 mg/ml), DMSO (10 mg/ml); Sparingly soluble in DMSO:PBS (1:1) (0.5 mg/ml)	2
Storage & Handling	Refrigerated (0-10°C); Store under inert gas; Light, air, and heat sensitive	4

Section 2: Pharmacology and Mechanism of Action

2.1. The Multifaceted Biological Activity of Taurolidine

Taurolidine exhibits a remarkable and complex pharmacological profile characterized by three primary, interconnected biological activities: broad-spectrum antimicrobial, potent anti-inflammatory/immunomodulatory, and investigational antineoplastic.[2] The foundation of these diverse effects lies in its unique chemical structure and its behavior in aqueous biological environments. The central event in its mechanism of action is its chemical decomposition upon contact with biological tissues, which liberates highly reactive methylol ($CH_2OH$) groups.[16] These electrophilic moieties are the primary effectors of its biological actions, capable of reacting non-specifically with nucleophilic groups, such as primary amino ($-NH_2$) and hydroxyl ($-OH$) groups, that are abundant on the surfaces of microbial cells, toxins, and host cells.[16] This fundamental chemical reactivity underpins all three pillars of its pharmacology.

2.2. Antimicrobial Mechanism: Cell Wall Disruption and Anti-Adherence Properties

The antimicrobial action of taurolidine is robust, well-characterized, and forms the basis of its primary clinical applications. Its activity is notable for its broad spectrum and its low propensity for inducing microbial resistance.

2.2.1. Spectrum of Activity

Taurolidine demonstrates cidal activity against an extensive range of microorganisms. This includes Gram-positive and Gram-negative bacteria, both aerobic and anaerobic, as well as mycobacteria and various clinically relevant fungi.[1] Its effectiveness extends to notoriously difficult-to-treat, antibiotic-resistant pathogens such as methicillin-resistant Staphylococcus aureus (MRSA) and vancomycin-resistant Enterococcus (VRE).[15] Recent in vitro studies have also confirmed its high activity against the emerging multidrug-resistant fungal pathogen Candida auris, with minimum inhibitory concentrations (MICs) well below the concentrations used in commercial catheter lock solutions.[19]

2.2.2. Primary Cidal and Anti-Adherence Mechanisms

The antimicrobial mechanism of taurolidine is fundamentally chemical rather than biological, which distinguishes it from conventional antibiotics that target specific enzymes or metabolic pathways.

1. Cell Wall Disruption: The primary cidal mechanism involves the liberated methylol groups, which act as alkylating agents. These groups form irreversible covalent bonds with the primary amino groups of peptidoglycan (murein) in bacterial cell walls and other surface components like lipopolysaccharides (LPS) in Gram-negative bacteria.[1] This extensive chemical modification leads to a catastrophic loss of structural integrity in the microbial cell wall, causing the leakage of essential intracellular contents and culminating in rapid cell death.[1]
2. Anti-Adherence Properties: A critical, and perhaps primary, step in many infections is the adherence of microbes to host tissues or indwelling medical devices. Taurolidine and its metabolites effectively inhibit this process. They are thought to mimic mannose, a sugar molecule often involved in bacterial adhesion. By binding to bacterial surface structures, such as the fimbriae of Escherichia coli, taurolidine physically blocks the bacteria from attaching to host epithelial cells and fibroblasts.[2] This anti-adhesive action is crucial for preventing the initial colonization that precedes biofilm formation and invasive infection.
3. Anti-Toxin Activity: Beyond its direct action on microbes, taurolidine can also neutralize the harmful effects of bacterial toxins. The reactive methylol groups bind to and denature both endotoxins (like LPS) and various exotoxins, rendering them biologically inactive.[1] This anti-endotoxin property is particularly relevant in preventing the systemic inflammatory cascade that leads to septic shock.[15]
4. Interaction with Virulence Factors: The mechanism extends to the neutralization of other specific virulence factors. For instance, in studies involving periodontal pathogens, taurolidine was shown to directly inhibit the enzymatic activity of Porphyromonas gingivalis gingipains, which are critical proteases for tissue destruction in periodontal disease.[20]

A significant clinical advantage derived from this non-specific, chemical mode of action is the extremely low probability of microbes developing resistance. Unlike antibiotics that target specific proteins which can mutate to confer resistance, it is far more difficult for a microbe to fundamentally alter its entire cell wall chemistry to evade the effects of methylol group alkylation. Consequently, the development of resistance to taurolidine is considered a rare or uncommon event, even with prolonged use.[8]

2.3. Anti-Inflammatory and Immunomodulatory Effects

In addition to its direct antimicrobial effects, taurolidine exerts potent anti-inflammatory and immunomodulatory actions that contribute to its therapeutic profile. These effects are mediated through both its taurine moiety and its reactive metabolites.

2.3.1. Cytokine Inhibition

A key anti-inflammatory mechanism of taurolidine is its ability to suppress the production and release of key pro-inflammatory cytokines. It has been shown to inhibit the synthesis of Tumor Necrosis Factor-alpha (TNF-α), Interleukin-1 (IL-1), IL-1β, IL-6, and IL-8 from various cell types, including peripheral blood mononuclear cells (PBMCs) and peritoneal cells.[7] This down-regulation of the inflammatory cascade helps to mitigate the excessive inflammation that can cause tissue damage during infection or after surgical trauma. Importantly, this cytokine-suppressing effect has been observed at taurolidine concentrations that are below the cytotoxic threshold for these immune cells, suggesting a specific modulatory action rather than a simple toxic effect.[7]

2.3.2. Immunomodulation and Leukocyte Interaction

The immunomodulatory properties of taurolidine are complex and dose-dependent. The taurine backbone of the molecule is believed to contribute to some of its immunoregulatory effects.[2] At higher concentrations, taurolidine exhibits dose- and time-dependent cytotoxicity towards leukocytes like PBMCs and granulocytes, which is consistent with its non-specific chemical reactivity and its antineoplastic properties.[7] For example, the IC50 concentrations for these cells after a 2-hour exposure were found to be around 500-520 µg/ml.[7] However, at lower, sub-toxic concentrations, it can modulate immune function without causing cell death. Furthermore, in the context of its anti-tumor activity, taurolidine has been reported to enhance the function of key anti-cancer immune cells, such as Natural Killer (NK) cells and cytotoxic T lymphocytes, thereby helping the immune system to recognize and eliminate malignant cells.[16]

2.4. Antineoplastic Mechanisms: Induction of Programmed Cell Death and Anti-Angiogenesis

The discovery of taurolidine's anti-cancer properties in the late 1990s opened a new avenue of research.[7] Its antineoplastic activity is multifaceted, engaging several distinct cellular pathways to inhibit tumor growth and induce cancer cell death.

2.4.1. Induction of Multiple Programmed Cell Death Pathways

Taurolidine's primary antineoplastic mechanism is the induction of programmed cell death in cancer cells, and it does so through a mixed modality that can include apoptosis, autophagy, necrosis, and necroptosis.[2] The predominant pathway engaged appears to be dependent on the specific cancer cell type being targeted.[17] This ability to trigger multiple death pathways may be an advantage, potentially overcoming resistance mechanisms that cancer cells might have to a single pathway.

2.4.2. Molecular Mechanisms of Apoptosis

The induction of apoptosis by taurolidine is well-documented and involves both the intrinsic (mitochondrial) and extrinsic pathways.[3] Key molecular events that have been observed include:

• Caspase Activation: It triggers the activation of caspases, the executive enzymes of the apoptotic cascade.[16]
• Mitochondrial Disruption: It disrupts the mitochondrial membrane potential, leading to the release of pro-apoptotic factors like cytochrome c and Apoptosis Inducing Factor (AIF) from the mitochondria into the cytoplasm.[10]
• DNA Damage and PARP Cleavage: In susceptible tumor cell lines, exposure to taurolidine leads to an increase in DNA fragmentation (observed as debris in the sub-G0/G1 phase of the cell cycle) and the cleavage of poly(ADP-ribose) polymerase (PARP), a hallmark of caspase-mediated apoptosis.[24]

2.4.3. Inhibition of Pro-Survival Signaling and Angiogenesis

Beyond directly triggering cell death, taurolidine also interferes with pathways that promote tumor survival and growth. In malignant mesothelioma cells, for instance, its cytotoxic effect is mediated by a combination of inducing oxidative stress and inhibiting the pro-survival Akt signaling pathway.[2] Furthermore, multiple reports indicate that taurolidine possesses anti-angiogenic properties, meaning it can inhibit the formation of new blood vessels that are essential for supplying nutrients to growing tumors and facilitating metastasis.[4]

The multifaceted nature of taurolidine's pharmacology suggests a powerful synergistic potential, particularly in clinical scenarios like cancer surgery. Surgical trauma itself can induce a state of immunosuppression and trigger the release of pro-inflammatory cytokines like TNF-α and IL-6, which can paradoxically promote the growth and spread of any residual tumor cells.[3] In this context, the administration of taurolidine could theoretically provide a "triple threat": it could (1) prevent bacterial contamination and infection at the surgical site, (2) suppress the surgery-induced, pro-tumorigenic inflammatory cascade by inhibiting cytokine release, and (3) directly kill any remaining microscopic cancer cells via apoptosis and autophagy. This integrated effect, where each mechanism reinforces the others, represents a therapeutic potential far greater than the sum of its individual parts.

However, the very mechanism that provides its broad-spectrum advantage—its non-specific chemical reactivity—also presents a potential limitation. This reactivity is not entirely exclusive to microbial or cancer cells. As demonstrated by its dose-dependent cytotoxicity to human leukocytes, there is a therapeutic window that must be respected.[7] The concentrations required to be effective against tumors (IC50 values of 40-80 µg/ml) are close to those that become toxic to immune cells after prolonged (24-hour) exposure (IC50 of 40 µg/ml).[7] This suggests that while its non-specific action is a powerful tool, it may limit the feasibility of high-dose systemic administration. Consequently, taurolidine's greatest therapeutic potential may lie in local or regional applications, such as catheter locks, intraperitoneal lavages, or direct local treatment of tumors, where high concentrations can be achieved at the target site with minimal systemic exposure and toxicity.[2]

Section 3: Pharmacokinetics and Metabolism

The pharmacokinetic profile of taurolidine is unique and is intrinsically linked to its mechanism of action. Understanding its absorption, distribution, metabolism, and elimination (ADME) is critical for optimizing its administration and interpreting its clinical effects. A central theme of its pharmacokinetics is its role as a pro-drug that is rapidly converted into active metabolites.

3.1. In Vitro and In Vivo Stability and Degradation Pathway

Taurolidine is chemically unstable in aqueous solutions, a property that is essential for its biological activity.[15] Upon exposure to an aqueous environment, it enters into an equilibrium with its active metabolites, taurultam and N-methylol-taurultam.[17] This initial hydrolysis step initiates a metabolic cascade that ultimately leads to its complete degradation into endogenous, non-toxic compounds. The full metabolic pathway proceeds as follows: Taurolidine is converted to taurultam and methylol-taurultam, which are then further metabolized to taurinamide. Finally, taurinamide is broken down into taurine (an endogenous amino acid), carbon dioxide, and water.[7]

In vitro studies using human blood have further elucidated this process. In isolated blood plasma, the concentrations of the derivatives taurultame and taurinamide remain relatively constant, suggesting that the plasma environment alone does not rapidly drive the full metabolic cascade.[25] However, in whole blood, a time- and concentration-dependent conversion is observed. The concentration of taurultame decreases over time, while the concentration of taurinamide increases at a corresponding rate, following logarithmic kinetics.[25] This difference between plasma and whole blood suggests that cellular components, such as red blood cells, play a significant role in facilitating the metabolism of taurolidine and its derivatives.

3.2. Distribution and Tissue Penetration

The distribution of taurolidine and its metabolites throughout the body is a key factor in its potential for systemic applications, such as cancer therapy. Pharmacokinetic studies conducted in glioblastoma patients receiving repeated intravenous infusions have provided crucial insights into its distribution characteristics.[25]

The volume of distribution ($V_d$)—a theoretical volume that quantifies the distribution of a drug in the body—was found to be markedly higher for taurolidine, taurultame, and taurinamide than the volume of blood plasma.[25] A high $V_d$ indicates that the drug is not confined to the circulatory system but distributes extensively into extravascular tissues. This is a critical finding, as it implies that the concentration of taurolidine and its active metabolites at the tissue level, such as within a solid tumor, is expected to be significantly higher than the concentrations measured concurrently in the plasma.[25] This extensive tissue penetration provides a strong pharmacokinetic rationale for investigating its use in treating solid tumors like glioblastoma, as it suggests that therapeutically effective concentrations can be achieved at the site of action.

3.3. Pharmacokinetics and Elimination

The pharmacokinetic profile of taurolidine after intravenous administration is characterized by a rapid rise and fall in plasma concentrations, necessitating specific dosing strategies for systemic use. In patients receiving repeated infusions, the calculated plasma concentrations of taurolidine increase sharply after the start of each infusion, continue to rise throughout the infusion period, and then decline rapidly once the infusion is stopped.[25]

The elimination half-lives of its primary metabolites have been determined. The terminal elimination half-life ($t_{1/2}$) for taurultam is approximately 1.5 hours, while the half-life for the downstream metabolite taurinamide is longer, at about 6 hours.[17] This indicates relatively rapid clearance from the systemic circulation. Regarding excretion, approximately 25% of an administered dose of taurolidine is ultimately eliminated by the kidneys in the form of taurinamide and/or taurine.[17]

The pharmacokinetic properties of taurolidine directly dictate the optimal strategies for its clinical administration, which differ profoundly based on the therapeutic goal. For systemic antineoplastic applications like the treatment of glioblastoma, where sustained plasma and tissue concentrations are required to exert an effect on tumor cells, the rapid decline in plasma levels post-infusion necessitates a regimen of repeated or continuous intravenous infusions.[25] This is precisely the conclusion reached by pharmacokinetic studies in this patient population. Conversely, for its primary approved use as a local catheter lock solution, this rapid systemic clearance is a paramount safety advantage. Any small amount of the drug that might inadvertently leak from the catheter lumen into the systemic circulation is quickly metabolized and eliminated, thereby minimizing the risk of systemic side effects.[17] This explains why the product labeling for catheter lock solutions explicitly states that they are not intended for systemic administration. Thus, the drug's pharmacokinetic profile is ideally suited for its local application and simultaneously defines the more complex administration requirements for its investigational systemic use.

Section 4: Clinical Efficacy in Infection Prevention and Treatment

The clinical utility of taurolidine is most firmly established in the prevention and, to a lesser extent, the treatment of infections associated with indwelling medical devices. A substantial body of evidence, including a pivotal Phase 3 clinical trial, meta-analyses, and comparative studies, supports its efficacy in reducing the incidence of catheter-related bloodstream infections (CRBSI). Furthermore, there is growing interest in its application for managing peritonitis, particularly in the context of peritoneal dialysis.

4.1. Prevention of Catheter-Related Bloodstream Infections (CRBSI)

CRBSIs are a frequent and severe complication for patients reliant on long-term central venous catheters (CVCs), leading to increased morbidity, mortality, and healthcare costs. Taurolidine-containing catheter lock solutions (CLS) have emerged as a highly effective strategy to mitigate this risk.

4.1.1. Pivotal Evidence: The LOCK-IT-100 Phase 3 Trial

The cornerstone of evidence supporting taurolidine's efficacy is the LOCK-IT-100 trial, which provided the basis for its FDA approval in the United States.[9] This large-scale, randomized, double-blind, active-control, multicenter Phase 3 study was designed to rigorously assess its effectiveness in a high-risk population: adult patients with kidney failure undergoing maintenance hemodialysis via a CVC.[29]

The trial compared a CLS containing taurolidine (13.5 mg/mL) and heparin (1000 U/mL), known as DefenCath, against the standard-of-care active control, a heparin-only (1000 U/mL) CLS.[29] The primary endpoint was the time to the first episode of CRBSI. The trial's Data and Safety Monitoring Board recommended its early termination based on a pre-specified interim analysis that demonstrated overwhelming efficacy with no safety concerns.[28]

The final analysis of the full study population (N=795) revealed a profound and statistically significant benefit for the taurolidine/heparin arm. Patients receiving the taurolidine-containing CLS experienced a 71% reduction in the risk of developing a CRBSI compared to those receiving heparin alone (Hazard Ratio: 0.29; 95% Confidence Interval: 0.14 to 0.62; p < 0.001).[9] The absolute event rates were 0.13 CRBSIs per 1000 catheter days in the taurolidine/heparin group versus 0.46 in the heparin group.[29] Interestingly, there were no significant differences between the two groups in the secondary endpoints of time to catheter removal for any reason or loss of catheter patency, indicating that the benefit was specific to infection prevention without compromising catheter function.[29] The LOCK-IT-100 trial provides Level 1 evidence that firmly establishes the superiority of a taurolidine/heparin CLS over heparin alone for CRBSI prevention in the hemodialysis population.

4.1.2. Efficacy in Hemodialysis and Parenteral Nutrition Populations

The findings of the LOCK-IT-100 trial are strongly supported by a broader body of literature from various clinical settings. Numerous studies, including randomized controlled trials (RCTs) and meta-analyses, have consistently demonstrated the benefit of taurolidine-containing lock solutions.[31]

In patients receiving home parenteral nutrition (HPN), a population also at high risk for CRBSI, a double-blind, placebo-controlled trial compared a 1.35% taurolidine lock solution to the standard-of-care 0.9% saline lock for the secondary prevention of recurrent infections.[34] The results were compelling: taurolidine use was associated with a 77% reduction in the rate of recurrent CRBSIs compared to saline (HR 0.23; p=0.009) and a 91% reduction in the rate of CVC removals due to CRBSI.[34] A 2013 meta-analysis that pooled data from six RCTs across both adult and pediatric populations reported an overall 66% reduced risk of CRBSI with the use of taurolidine lock solutions.[18] Furthermore, extensive observational data from hemodialysis centers in Europe, where taurolidine-containing products like Neutrolin® and TauroLock® have been available for years, corroborate these findings, showing marked reductions in CRBSI rates in real-world clinical practice.[8]

4.1.3. Application in Pediatric and Oncology Patients

The benefits of taurolidine lock therapy extend to other vulnerable patient populations, including children and cancer patients.

• Pediatric Population: A systematic review and meta-analysis focusing specifically on pediatric patients, which included four RCTs, found that taurolidine use led to a statistically significant reduction in both the total number of CRBSI events (Relative Risk: 0.23) and the incidence rate of CRBSI per 1000 catheter days (Mean Difference: -1.12).[18] While these results are promising, the authors noted that the methodological quality of the included studies was not high, indicating a need for further high-quality research in this population.[18]
• Oncology Population: Cancer patients with long-term CVCs for chemotherapy are another high-risk group. Pilot studies and retrospective analyses have shown that taurolidine lock therapy is not only effective for preventing CRBSI but can also be a beneficial adjunctive therapy for treating established infections, particularly in cases that are resistant to systemic antibiotic therapy.[5] These studies report that the application is feasible, safe, and can lead to complete recovery from infection, often allowing for the salvage of the implanted device.[6]

4.2. Role in the Management of Peritonitis

While its primary modern application is in CRBSI prevention, taurolidine's historical roots are in the management of peritonitis, and it is now being reinvestigated for this purpose in the context of peritoneal dialysis (PD).

4.2.1. Historical Use as an Intraperitoneal Lavage

As previously noted, taurolidine was originally developed and used as an intraperitoneal lavage solution during surgery to treat and prevent peritonitis.[1] Its broad-spectrum antimicrobial and anti-endotoxin properties made it well-suited for this local application.

4.2.2. Investigational Use in Peritoneal Dialysis (PD)-Associated Peritonitis

PD-associated peritonitis is a major complication that frequently leads to catheter removal and technique failure, forcing patients to transition to hemodialysis. There is emerging evidence that taurolidine lock therapy may offer a new strategy to manage this condition, especially in difficult cases. Small retrospective series and case reports suggest that a taurolidine-urokinase lock therapy is a viable and safe adjunctive treatment for recurrent or refractory PD peritonitis, particularly when caused by biofilm-forming or multidrug-resistant (MDR) organisms.[37]

These studies report high rates of clinical and microbiological resolution, enabling catheter salvage in patients who might otherwise have lost their PD access.[38] The therapy has been successfully used against challenging pathogens like Pseudomonas aeruginosa, which are notoriously difficult to eradicate.[40] However, treatment failures have been reported, notably in cases of Staphylococcus aureus peritonitis and in one case of fungal peritonitis, where the treatment was halted due to severe pain upon intraperitoneal administration.[41] When tolerated, adverse events are typically mild and transient, consisting mainly of abdominal discomfort.[37]

This emerging data points toward a potential paradigm shift in the management of PD peritonitis. Recurrent and refractory infections are often attributed to the formation of a resilient biofilm within the PD catheter, which is poorly penetrated by systemic antibiotics.[37] Current management often fails, necessitating catheter removal.[41] The use of a taurolidine-urokinase lock represents a strategy that directly targets the source of the infection—the catheter biofilm—by delivering a high local concentration of an antimicrobial (taurolidine) and a fibrinolytic agent (urokinase) to disrupt the biofilm matrix. If these promising early findings are validated in larger, prospective trials, this approach could fundamentally alter the treatment algorithm for PD peritonitis, moving from a focus on systemic treatment and frequent catheter removal to a more effective catheter-salvage strategy.

4.3. Comparative Efficacy Analyses

A crucial aspect of evaluating any new therapy is comparing it to existing alternatives. Taurolidine has been compared, both directly and indirectly, to other common catheter lock solutions.

4.3.1. Taurolidine vs. Heparin and Saline Lock Solutions

As established by the LOCK-IT-100 trial, a taurolidine/heparin solution is unequivocally superior to a heparin-only lock for CRBSI prevention in hemodialysis patients.[29] Similarly, the RCT in HPN patients demonstrated the superiority of a 1.35% taurolidine lock over a 0.9% saline lock.[34] These findings are consistent across multiple meta-analyses, which confirm that antimicrobial lock solutions as a class, with taurolidine being a prominent example, are significantly more effective than heparin alone for preventing CRBSI.[33]

4.3.2. Taurolidine vs. Citrate-Based Lock Solutions

Citrate is another non-antibiotic antimicrobial agent used in catheter lock solutions. A large, multicenter, retrospective observational study involving 1,514 hemodialysis patients provided the most substantial comparison to date between taurolidine- and citrate-based lock solutions.[44] The study found that patients using taurolidine-based locks had a significantly lower hazard for CVC removal due to either infection or catheter malfunction compared to patients using either low-concentration (4% or 30%) or high-concentration (46.7%) citrate solutions (HR 0.34).[45] While these findings suggest that taurolidine may be superior to citrate, the authors appropriately caution that due to the retrospective, non-randomized nature of the study, these conclusions should be interpreted with care pending confirmation from prospective RCTs.[44]

4.3.3. Taurolidine vs. Ethanol Lock Therapy (ELT)

Ethanol lock therapy (ELT) is another effective strategy for CRBSI prevention but has been associated with concerns about mechanical damage to catheters. A unique retrospective study in pediatric intestinal failure patients who had sequentially used both ELT and taurolidine lock therapy (TLT) provided a direct within-patient comparison.[46]

The study found no statistically significant difference in the rates of CRBSI between the two therapies (0.83 events/1000 catheter days for TLT vs. 2.03 for ELT; p=0.25).[46] However, there was a dramatic and highly significant difference in the rates of mechanical complications. TLT was associated with significantly lower rates of CVC breaks, occlusions, and repairs compared to ELT.[46] This evidence highlights a critical, and perhaps underappreciated, benefit of taurolidine. While its infection prevention capability may be comparable to other potent agents like ethanol, its superior profile in maintaining the physical integrity of the catheter is a major advantage. For patients with chronic conditions and limited long-term vascular access, such as those in the pediatric intestinal failure population, preserving the lifespan of each CVC is as vital as preventing infection. Each line loss due to mechanical failure reduces future access options. Therefore, the value proposition of taurolidine extends beyond simple infection prevention to the broader and more clinically impactful goal of long-term vascular access preservation.

Table 2: Summary of Key Clinical Trials Evaluating Taurolidine for CRBSI Prevention

Study Identifier / Type	Patient Population	No. of Patients	Intervention	Comparator	Primary Outcome	Key Result	Source(s)
LOCK-IT-100 (Phase 3 RCT)	Adult Hemodialysis (HD) with CVC	795	Taurolidine/Heparin CLS	Heparin CLS	Time to CRBSI	71% reduction in CRBSI risk (HR 0.29, p<0.001)	29
RCT (Demirok et al.)	Adult Chronic Intestinal Failure (CIF) on HPN	61	1.35% Taurolidine CLS	0.9% Saline CLS	Recurrent CRBSI	77% reduction in recurrent CRBSI rate (HR 0.23, p=0.009)	34
Meta-analysis (Pediatric)	Pediatric patients with CVC	4 RCTs	Taurolidine CLS	Control (Heparin/Saline)	Total number of CRBSI	Significant reduction in CRBSI (RR 0.23)	18
Meta-analysis (Mixed Pop.)	Adult and Pediatric HD, PN, Oncology	6 RCTs	Taurolidine CLS	Heparin CLS	Incidence of CRBSI	66% reduced risk of CRBSI (RR 0.34)	32

Table 3: Comparative Efficacy of Taurolidine vs. Other Catheter Lock Solutions

Comparator Agent	Key Efficacy Finding (CRBSI)	Key Finding (Mechanical Complications / Patency)	Study Type	Source(s)
Heparin	Superior to heparin (71% risk reduction)	No significant difference in patency loss or catheter removal	Phase 3 RCT	29
Citrate	Associated with lower risk of CVC removal for infection	Associated with lower risk of CVC removal for malfunction	Retrospective Cohort	44
Ethanol	No significant difference in CRBSI rates	Significantly lower rates of CVC breaks, occlusions, and repairs with Taurolidine	Retrospective Cohort	46

Section 5: Investigational Antineoplastic Applications

While taurolidine is established as an anti-infective agent, its potential as a cancer therapeutic remains investigational. A substantial body of preclinical research has elucidated its anti-cancer mechanisms, but clinical evidence is still in early stages and has yielded mixed results. A critical evaluation of the available data is essential to form a balanced perspective on its future role in oncology.

5.1. Preclinical Evidence and Rationale for Cancer Therapy

The rationale for investigating taurolidine in cancer is built upon robust preclinical data demonstrating its potent and selective cytotoxicity against malignant cells.

• In Vitro Activity: Laboratory studies have consistently shown that taurolidine inhibits the growth of a wide array of human and murine tumor cell lines, including those from ovarian cancer, glioma, and melanoma.[2] It typically exhibits IC50 values (the concentration required to inhibit growth by 50%) in the low micromolar range, from 9.6 to 34.2 µM.[24]
• Mechanism of Action: The primary mechanism of its anti-cancer effect is the induction of programmed cell death, particularly apoptosis. This has been demonstrated through multiple lines of evidence, including an increase in annexin-V binding (a marker of early apoptosis), cleavage of PARP by caspases, and fragmentation of DNA.[2] A key finding from these early studies was the selectivity of this effect; taurolidine induced apoptosis in tumor cells while having a minimal apoptotic effect on normal cells, such as murine fibroblasts, suggesting a potential therapeutic window.[24]
• Animal Models: The promising in vitro results have been translated into animal models. In nude mice bearing intraperitoneal xenografts of human ovarian tumors, systemic administration of taurolidine was shown to significantly inhibit both the formation of tumors and the growth of established tumors.[24]

However, the preclinical picture is not entirely uniform. A recent in vitro study investigating the effect of taurolidine on colon cancer cell lines introduced a note of caution.[50] While confirming its cytotoxic effects, the researchers observed that taurolidine exposure also appeared to enhance the detachment of adherent cancer cells when subjected to mechanical stress. This raised a theoretical concern that, in certain contexts, taurolidine could potentially mobilize cancer cell conglomerates, which might have implications for metastatic spread. This finding is preliminary and requires significant further investigation in in vivo models to determine its clinical relevance, but it highlights the complexity of the drug's interaction with tumor cells and their microenvironment.

5.2. Clinical Investigations in Glioblastoma

Glioblastoma is an aggressive primary brain tumor with a dismal prognosis, making it a prime target for novel therapeutic strategies. The preclinical evidence showing a selective antineoplastic effect on glial and neuronal tumor cells provided a strong rationale for investigating taurolidine in this disease.[49]

Early clinical experience was documented in a case report of two patients with progressive glioblastoma who had exhausted conventional therapeutic options.[52] Both patients received high-dose intravenous taurolidine (20 g/day). The treatment was associated with a transient but marked improvement in their neurological condition and quality of life, and follow-up imaging demonstrated partial remission of their tumors.[54] Despite this clear, albeit temporary, response to treatment, the prognosis remained poor; both patients died approximately four months after initiating taurolidine therapy from causes unrelated to tumor progression (one from pneumonia, the other from acute thrombembolism).[52]

This promising initial experience led to the initiation of a formal Phase I dose-escalation clinical trial (NCT00022360) designed to determine the maximum tolerated dose (MTD), safety, and pharmacokinetics of intravenous taurolidine in patients with recurrent high-grade glioma.[55] The results of this trial are not available in the provided documentation. Recognizing the challenges of systemic delivery to the brain, other research has explored local delivery strategies. One such approach involves embedding taurolidine within a fibrin sealant matrix, which can be applied directly into the tumor resection cavity. In vitro studies of this method demonstrated sustained release of therapeutically effective amounts of the drug over a two-week period, with the released drug retaining its ability to inhibit tumor cell proliferation.[56]

5.3. Clinical Investigations in Gastrointestinal and Other Malignancies

The most significant clinical trial of taurolidine as an antineoplastic agent to date was conducted in patients with gastrointestinal cancers. This multicenter, prospective, randomized controlled trial included 120 patients undergoing surgery for resectable colorectal, gastric, or pancreatic cancer.[57] Patients were randomized to receive an intraperitoneal lavage with either a 0.5% taurolidine/heparin solution or a control solution of 0.25% povidone-iodine.

The study yielded mixed results. On a mechanistic level, the taurolidine lavage was successful, demonstrating a significant reduction in the intraperitoneal concentrations of several pro-inflammatory and pro-tumorigenic cytokines, including IL-1β, IL-6, and IL-10.[57] This finding was corroborated by a separate study in colon cancer patients, which showed that peri-operative intravenous taurolidine significantly attenuated systemic circulating IL-6 levels in the first week after surgery.[60]

However, despite these favorable effects on biological markers, the trial failed to demonstrate a benefit in terms of clinical outcomes. After a median follow-up of 50 months, there were no statistically significant differences between the taurolidine group and the control group in overall mortality, cancer-related death rate, local recurrence rate, or the rate of distant metastasis.[57] Another multicenter, randomized, placebo-controlled trial was initiated in Europe to evaluate the anti-neoplastic effects of taurolidine in patients undergoing surgery for non-metastatic colon cancer (EudraCT 2008-005570-12), but its results are listed as unavailable.[61]

This presents a significant and cautionary disconnect between biomarker efficacy and clinical outcomes. The data confirm that taurolidine can effectively modulate the pro-tumorigenic inflammatory environment associated with surgery. Yet, in the largest trial conducted, this modulation was insufficient to alter the long-term course of the disease in terms of recurrence or survival. This critical finding tempers the enthusiasm generated by the strong preclinical data and underscores the profound challenge of translating promising mechanistic effects into tangible clinical benefits for cancer patients. It suggests that the anti-inflammatory action of taurolidine alone, when applied as a one-time lavage, may not be potent enough to overcome the complex drivers of cancer progression post-resection.

5.4. Future Directions and Unresolved Questions

The literature consistently concludes that the role of taurolidine as a chemotherapeutic agent is not yet established and that there is a clear lack of gold-standard, Level 1 randomized clinical trials to validate its potential benefits.[3] The existing clinical data, particularly when viewed as a whole, points toward a "local versus systemic" conundrum. Its most promising effects have been seen in local applications (peritoneal lavage, case reports of IV use for brain tumors where it achieves high tissue concentration), while its largest trial evaluating a regional application failed to show a survival benefit. This, combined with its pharmacokinetic profile, strongly suggests that its future as a cancer therapeutic may be more promising in targeted, local/regional applications rather than as a broad systemic agent.

Key unresolved questions remain. The optimal dose, administration route (e.g., intravenous vs. local), and schedule have not been determined. Its potential in combination with standard-of-care chemotherapy or emerging immunotherapies is an unexplored but potentially fruitful area of research. Finally, the clinical relevance of the in vitro finding of enhanced cancer cell detachment must be investigated to ensure its safety in the oncologic setting. Until these questions are addressed in well-designed, adequately powered clinical trials, the role of taurolidine in modern cancer treatment remains uncertain.

Section 6: Safety, Tolerability, and Risk Profile

A comprehensive understanding of a drug's safety profile is paramount for its clinical use. Taurolidine has been used in various clinical settings for several decades, providing a substantial basis for evaluating its safety and tolerability. It is crucial to differentiate between adverse events associated with taurolidine itself and those related to the combination products in which it is frequently formulated.

6.1. Comprehensive Safety Profile and Adverse Event Analysis

Overall, taurolidine is considered to have a favorable safety profile and is generally well-tolerated, particularly when used locally as a catheter lock solution.[10] Even when administered intravenously at high doses (up to 20-40 grams daily) in investigational cancer trials, it was reported to be safe and well-tolerated with no significant systemic side effects identified.[21]

A large retrospective cohort study of 470 home parenteral nutrition patients provided detailed insights into adverse events (AEs) associated with taurolidine-containing CLS.[62] In this cohort, 19% of patients reported at least one mild-to-severe AE related to the lock solution. The most common symptom was pain upon instillation of the lock. However, a critical finding of this study was that over half (51%) of all reported AEs were ultimately determined to be related to underlying problems with the vascular access device itself (e.g., fibrin sheath, incorrect catheter tip placement) rather than a direct pharmacological effect of taurolidine. This distinction is clinically significant. Upon investigation and correction of the catheter-related issue, 85% of these patients were able to successfully resume using the taurolidine lock solution without a recurrence of symptoms. This suggests that many AEs attributed to the drug are, in fact, manifestations of a device interaction. Pain upon instillation, therefore, should not be reflexively interpreted as a drug intolerance but should prompt a thorough investigation of the catheter's integrity and function. True allergic reactions to taurolidine were found to be rare, occurring in only 6 of the 470 patients (1.3%).[62]

The safety profile of the FDA-approved combination product, DefenCath (taurolidine/heparin), was established in the LOCK-IT-100 trial.[64] The most frequently reported adverse reactions occurring in ≥2% of patients were hemodialysis catheter malfunction (17%), hemorrhage/bleeding (7%), nausea (7%), vomiting (6%), dizziness (6%), musculoskeletal chest pain (3%), and thrombocytopenia (2%). Importantly, the overall safety profile of DefenCath was found to be comparable to that of the heparin-only control arm, with similar rates of serious adverse events and discontinuations.[29] This finding implies that the incremental risk added by taurolidine itself, when used as a CLS, is minimal. The majority of the safety burden in this context appears to be driven by the indwelling catheter and the co-administered anticoagulant, heparin. This "heparin confounder" is important for accurately assessing the risk-benefit ratio of adding taurolidine to a CLS regimen.

6.2. Contraindications and High-Risk Populations

The contraindications listed for the commercial product DefenCath are primarily related to its heparin component. It is contraindicated in patients with:

• A known history of heparin-induced thrombocytopenia (HIT).[64]
• Known hypersensitivity to taurolidine, heparin, the citrate excipient used in the formulation, or pork products (from which heparin is derived).[64]

Regarding specific populations:

• Pregnancy and Lactation: When used as a CLS, taurolidine is not intended for systemic administration. Therefore, maternal use is not expected to result in significant fetal or infant exposure to the drug.[26]
• Pediatric Use: The safety and effectiveness of the DefenCath combination product have not been formally established in pediatric patients in the U.S..[27] However, other taurolidine-containing lock solutions, such as TauroLock™, are widely used in pediatric populations in Europe and Australia under local guidelines.[68]

6.3. Clinically Significant Drug Interactions

While formal drug interaction studies are limited, database analyses have identified potential interactions based on pharmacological principles.

• Risk of Methemoglobinemia: There is a theoretical potential for an increased risk or severity of methemoglobinemia when taurolidine is combined with certain local anesthetics, including butacaine, capsaicin, lidocaine, procaine, and tetracaine.[1] Methemoglobinemia is a condition where an abnormal amount of methemoglobin is produced, which cannot effectively carry oxygen.
• Risk of Immunosuppression: The risk or severity of immunosuppression may be increased when taurolidine is combined with immunomodulatory drugs such as Etrasimod.[1]

6.4. Toxicological Profile and Mutagenicity Data

Toxicological studies have been conducted to assess the long-term safety of taurolidine.

• Carcinogenesis: Formal carcinogenicity studies in animals have not been conducted with taurolidine.[64]
• Mutagenesis: The mutagenicity data for taurolidine is mixed. It tested positive in two in vitro assays: the Ames reverse mutation assay and the L5178Y mouse lymphoma cell assay. However, it tested negative in a more comprehensive in vivo combined micronucleus test and comet assay in rats, even at the highest dose tested. This pattern suggests a low potential for mutagenicity in vivo.[64]

Table 4: Adverse Reactions Associated with Taurolidine-Containing Products (≥2% Incidence in Pivotal Trial)

Adverse Reaction	DEFENCATH (N=398) N (%)	Heparin (N=399) N (%)
Hemodialysis catheter malfunction	68 (17%)	47 (12%)
Hemorrhage/bleeding	27 (7%)	34 (9%)
Nausea	28 (7%)	44 (11%)
Vomiting	24 (6%)	32 (8%)
Dizziness	22 (6%)	16 (4%)
Musculoskeletal chest pain	11 (3%)	7 (2%)
Thrombocytopenia	7 (2%)	4 (1%)
Data from the LOCK-IT-100 Phase 3 clinical trial.64

Section 7: Regulatory Status and Commercial Formulations

The global regulatory landscape for taurolidine is complex and varies significantly by region, reflecting different regulatory philosophies regarding products used at the drug-device interface. This has resulted in its classification as a drug in the United States but as a medical device in Europe and Australia.

7.1. Regulatory Pathway and Approval in the United States (FDA)

In the United States, the combination product of taurolidine and heparin is regulated as a drug.

• Product: DefenCath® Catheter Lock Solution.
• Manufacturer: CorMedix Inc..[9]
• Approval Date: November 15, 2023.[9]
• Indication: DefenCath is indicated to reduce the incidence of catheter-related bloodstream infections (CRBSI) in the limited population of adult patients with kidney failure receiving chronic hemodialysis (HD) through a central venous catheter (CVC).[1]
• Regulatory Pathway: The FDA approved DefenCath under the Limited Population Pathway for Antibacterial and Antifungal Drugs (LPAD). This pathway is designed to expedite the development and approval of drugs that address unmet needs in small, specific patient populations.[30] In addition to the LPAD pathway, DefenCath also received Fast Track and Qualified Infectious Disease Product (QIDP) designations, which further accelerated its review process.[30]

7.2. CE Mark Approval and Status in Europe

In the European Union, taurolidine-containing lock solutions are regulated as Class III medical devices, which are high-risk devices that require rigorous review by a notified body. This classification means they do not undergo the centralized marketing authorization process via the European Medicines Agency (EMA) that is typical for medicinal products.[70]

• Product: Neutrolin® (manufactured by CorMedix Inc.) received its CE Mark approval in July 2013. This allows it to be marketed throughout the EU for the prevention of CRBSI and maintenance of catheter patency in hemodialysis patients.[35]
• Product: The TauroLock™ family of products (manufactured by TauroPharm GmbH) also possesses CE marking and is widely available in Europe. These products are indicated for instillation into venous access devices to provide infection control and ensure patency.[72]

This divergent regulatory classification—drug in the US versus medical device in the EU—is not arbitrary. It reflects a fundamental difference in how the product's primary function is interpreted. The "medical device" classification in Europe focuses on the product's local action within the device (the catheter), where it creates an environment hostile to microbial growth, thus acting as a functional part of the catheter system.[72] In contrast, the "drug" classification by the FDA focuses on the product's pharmacological action to achieve a systemic clinical outcome for the patient—the reduction of bloodstream infections.[65] This distinction has significant implications for the type of evidence required for approval and for post-market surveillance in each region.

7.3. Registration in Australia (TGA)

Australia's regulatory approach aligns with that of the European Union. The Therapeutic Goods Administration (TGA) lists taurolidine-containing catheter lock solutions on the Australian Register of Therapeutic Goods (ARTG) as Class III medical devices.[75] Tauropharm Australia Pty Ltd has had several Taurolock™ products, including Taurolock HEP 100 and Taurolock HEP 500, listed on the ARTG since 2016.[75] Its use is integrated into the clinical practice of major Australian healthcare institutions, as evidenced by hospital-specific administration guidelines.[68]

7.4. Overview of Available Commercial Formulations and Their Composition

The availability of multiple taurolidine formulations reflects a sophisticated tailoring of the product to meet the specific clinical needs of diverse patient populations who rely on CVCs. Each formulation balances antimicrobial action with varying degrees of anticoagulation or fibrinolysis.

• DefenCath® (U.S.): A sterile, single-dose solution containing Taurolidine (13.5 mg/mL) and Heparin (1,000 USP Units/mL) in a citrate buffer.[9]
• Neutrolin® (E.U.): A formulation of Taurolidine (1.35%) and Heparin (1,000 U/mL).[70]
• TauroLock™ Family (E.U., Australia, etc.): This family offers a range of options:
• TauroLock™: The base formulation containing Taurolidine (1.35%) and Citrate (4%) for both antimicrobial and mild anticoagulant effects.[73]
• TauroLock™-HEP100: Adds a low dose of Heparin (100 IU/mL) to the taurolidine/citrate base. It is often used in oncology and pediatric patients who may require less aggressive anticoagulation.[68]
• TauroLock™-HEP500: Contains a higher dose of Heparin (500 IU/mL) and is primarily targeted at hemodialysis patients who have a greater risk of thrombosis.[74]
• TauroLock™-U25,000: For patients with persistent catheter occlusion issues, this formulation combines the taurolidine/citrate base with the fibrinolytic agent Urokinase (25,000 IU) to actively dissolve existing clots.[37]
• NutriLock™: A specialized formulation containing only Taurolidine as the active antimicrobial ingredient, with no citrate or heparin. It is designed for patients, such as those on parenteral nutrition, where any anticoagulant effect is undesirable or contraindicated.[74]

This array of formulations demonstrates a clear evolution driven by specific clinical challenges—infection, thrombosis risk, or established clots—faced by different patient subgroups. It represents not a one-size-fits-all approach but a versatile toolkit of tailored solutions for CVC maintenance.

Table 5: Global Regulatory Status and Commercial Formulations of Taurolidine

Region / Agency	Product Name(s)	Manufacturer	Regulatory Classification	Approved Indication(s)	Key Components	Source(s)
United States (FDA)	DefenCath®	CorMedix Inc.	Drug (LPAD Pathway)	Reduction of CRBSI in adult HD patients with a CVC.	Taurolidine, Heparin, Citrate	9
European Union (CE Mark)	Neutrolin®, TauroLock™ family	CorMedix Inc., TauroPharm GmbH	Medical Device (Class III)	Prevention of CRBSI and maintenance of catheter patency.	Varies: Taurolidine, Citrate, Heparin, Urokinase	70
Australia (TGA)	Taurolock™ family	Tauropharm Australia Pty Ltd	Medical Device (Class III)	Non-antibiotic-based antimicrobial catheter lock solution.	Taurolidine, Citrate, Heparin	75

Section 8: Synthesis and Expert Recommendations

8.1. Summary of Key Findings and Clinical Implications

This comprehensive analysis of taurolidine reveals it to be a unique therapeutic agent with a well-defined role in infection prevention and an intriguing, though unproven, potential in oncology. Its core strength lies in its taurine-derived structure, which, upon hydrolysis, unleashes a non-specific chemical attack on microbial structures. This mechanism confers several key advantages: a broad spectrum of antimicrobial activity, the ability to neutralize bacterial toxins, and a notably low propensity for inducing microbial resistance—a critical attribute in the current era of antimicrobial stewardship.

The clinical evidence supporting its use as a catheter lock solution for the prevention of CRBSI is robust and compelling. The pivotal LOCK-IT-100 trial provides Level 1 evidence of its superiority over heparin in the high-risk adult hemodialysis population. This is corroborated by a wealth of data from meta-analyses and observational studies across diverse patient populations, including those on parenteral nutrition and pediatric patients. A significant, and perhaps under-recognized, clinical implication is its favorable safety profile with respect to catheter integrity. Comparative data suggests that, unlike ethanol lock therapy, taurolidine prevents infections without increasing the risk of mechanical catheter complications, a crucial benefit for patients with limited long-term vascular access.

In contrast, its role as an antineoplastic agent remains firmly investigational. While preclinical studies and early biomarker data are promising—demonstrating selective induction of cancer cell death and modulation of the pro-tumorigenic inflammatory response—this has not yet translated into a proven clinical benefit in terms of patient survival in major randomized trials. This disconnect highlights the significant translational gap that must be bridged before taurolidine can be considered for a role in modern cancer therapy.

8.2. Recommendations for Clinical Practice and Catheter Care Protocols

Based on the totality of the evidence, the following recommendations for clinical practice can be made:

1. Standard of Care for Hemodialysis: In line with the results of the LOCK-IT-100 trial and its subsequent FDA approval, the use of a taurolidine/heparin catheter lock solution should be considered the standard of care for the prevention of CRBSI in adult patients with kidney failure receiving chronic hemodialysis through a CVC.
2. Consideration in Other High-Risk Populations: The strong evidence from meta-analyses and RCTs supports the consideration of taurolidine-based lock solutions for CRBSI prevention in other high-risk groups, including adult and pediatric patients on home parenteral nutrition and oncology patients with long-term CVCs. The choice of formulation (with or without heparin/citrate) should be tailored to the patient's specific risk of thrombosis.
3. Management of Adverse Events: Clinicians should adopt a diagnostic approach to adverse events, particularly pain upon instillation of the lock solution. Based on evidence that such symptoms often indicate an underlying catheter-related mechanical issue, an immediate investigation of catheter function and tip position is warranted before discontinuing the therapy due to perceived intolerance.
4. Catheter Salvage in PD Peritonitis: For patients with refractory or recurrent peritoneal dialysis-associated peritonitis, particularly when a biofilm-related infection is suspected, taurolidine-urokinase lock therapy should be considered as a viable catheter-salvage strategy before proceeding to catheter removal.

8.3. Recommendations for Future Research and Development

While the role of taurolidine in CRBSI prevention is well-established, significant questions remain, and further research is needed to optimize its use and explore its full therapeutic potential.

1. Infection Prevention: Future research should focus on large-scale, prospective, randomized controlled trials that directly compare taurolidine-based solutions against other leading non-antibiotic lock solutions, such as high-concentration citrate and ethanol. The primary endpoints of such trials should include not only CRBSI rates but also rates of mechanical catheter complications, catheter patency, and overall catheter survival to definitively establish superiority.
2. Peritonitis Management: The promising but preliminary findings for taurolidine-urokinase lock therapy in PD-associated peritonitis must be validated. A multicenter, randomized controlled trial is urgently needed to confirm its efficacy and safety and to establish optimal treatment protocols (dosing, duration) for this indication.
3. Oncology: The path forward for taurolidine in oncology requires a strategic re-evaluation. Future clinical trials should move beyond monotherapy in broad settings and instead:

• Investigate its potential in combination with standard-of-care chemotherapy or immunotherapy, where its anti-inflammatory and immunomodulatory effects might be synergistic.
• Focus on localized delivery mechanisms (e.g., drug-eluting matrices, improved intraperitoneal administration protocols) to maximize drug concentration at the tumor site while minimizing systemic exposure.
• Conduct rigorous in vivo studies to address the preclinical finding of enhanced cancer cell detachment to confirm its safety profile in the context of metastatic disease.

4. Pharmacology: Further basic science research is warranted to fully elucidate the specific molecular targets of taurolidine's reactive methylol groups on both microbial and mammalian cells. A deeper understanding of these interactions could help in designing next-generation derivatives with an even more favorable therapeutic index, maximizing efficacy while minimizing any potential for off-target effects.

Works cited

1. Taurolidine: Uses, Interactions, Mechanism of Action | DrugBank ..., accessed October 25, 2025, https://go.drugbank.com/drugs/DB12473
2. Taurolidine (CAS Number: 19388-87-5) | Cayman Chemical, accessed October 25, 2025, https://www.caymanchem.com/product/15374/taurolidine
3. The Evolving Role of Taurolidine in Cancer Therapy - AMiner, accessed October 25, 2025, https://www.cn.aminer.org/pub/53e9b90ab7602d97044ef1ff
4. Taurolidine 19388-87-5 | Tokyo Chemical Industry Co., Ltd.(JP), accessed October 25, 2025, https://www.tcichemicals.com/JP/en/p/T3980
5. Taurolidine is effective in the treatment of central venous catheter, related bloodstream infections in cancer patints - ResearchGate, accessed October 25, 2025, https://www.researchgate.net/publication/8201931_Taurolidine_is_effective_in_the_treatment_of_central_venous_catheter_related_bloodstream_infections_in_cancer_patints
6. Taurolidine is effective in the treatment of central venous catheter-related bloodstream infections in cancer patients - PubMed, accessed October 25, 2025, https://pubmed.ncbi.nlm.nih.gov/15519483/
7. The Antiseptic and Antineoplastic Agent Taurolidine Modulates Key Leukocyte Functions, accessed October 25, 2025, https://iv.iiarjournals.org/content/36/5/2074
8. A 2% taurolidine catheter lock solution prevents catheter-related bloodstream infection (CRBSI) and catheter dysfunction in hemodialysis patients | British Journal of Nursing - MAG Online Library, accessed October 25, 2025, https://www.magonlinelibrary.com/doi/10.12968/bjon.2021.30.14.S24
9. DefenCath (taurolidine and heparin) FDA Approval History - Drugs ..., accessed October 25, 2025, https://www.drugs.com/history/defencath.html
10. The evolving role of taurolidine in cancer therapy - PubMed, accessed October 25, 2025, https://pubmed.ncbi.nlm.nih.gov/20039217/
11. CHEBI:135173 - taurolidine - EMBL-EBI, accessed October 25, 2025, https://www.ebi.ac.uk/chebi/searchId.do?chebiId=CHEBI:135173
12. taurolidine | Ligand page | IUPHAR/BPS Guide to PHARMACOLOGY, accessed October 25, 2025, https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=13030
13. en.wikipedia.org, accessed October 25, 2025, https://en.wikipedia.org/wiki/Taurolidine#:~:text=floccosum%2C%20Pityrosporum%20ovale.-,Chemical%20properties,off%20white%20odourless%20crystalline%20powder.
14. Taurolidine | CAS 19388-87-5 | SCBT - Santa Cruz Biotechnology, accessed October 25, 2025, https://www.scbt.com/p/taurolidine-19388-87-5
15. Taurolidine Antiadhesive Properties on Interaction with E. coli; Its Transformation in Biological Environment and Interaction with Bacteria Cell Wall - PubMed Central, accessed October 25, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC2812514/
16. What is the mechanism of Taurolidine? - Patsnap Synapse, accessed October 25, 2025, https://synapse.patsnap.com/article/what-is-the-mechanism-of-taurolidine
17. TAUROLIDINE - New Drug Approvals, accessed October 25, 2025, https://newdrugapprovals.org/2022/01/18/taurolidine/
18. Taurolidine lock solution for catheter-related bloodstream infections in pediatric patients: A meta-analysis | PLOS One - Research journals, accessed October 25, 2025, https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0231110
19. In vitro activity of taurolidine against clinical Candida auris isolates: relevance to catheter-related bloodstream infections | Antimicrobial Agents and Chemotherapy - ASM Journals, accessed October 25, 2025, https://journals.asm.org/doi/10.1128/aac.00381-24
20. Taurolidine Acts on Bacterial Virulence Factors and Does Not Induce Resistance in Periodontitis-Associated Bacteria—An In-Vitro Study - MDPI, accessed October 25, 2025, https://www.mdpi.com/2079-6382/9/4/166
21. Taurolidine - Wikipedia, accessed October 25, 2025, https://en.wikipedia.org/wiki/Taurolidine
22. (PDF) The Effectiveness of Taurolidine Antimicrobial Locks in Preventing Catheter-Related Bloodstream Infections (CRBSIs) in Children Receiving Parenteral Nutrition: A Case Series - ResearchGate, accessed October 25, 2025, https://www.researchgate.net/publication/383805950_The_Effectiveness_of_Taurolidine_Antimicrobial_Locks_in_Preventing_Catheter-Related_Bloodstream_Infections_CRBSIs_in_Children_Receiving_Parenteral_Nutrition_A_Case_Series
23. The antibacterial substance taurolidine exhibits anti-neoplastic action based on a mixed type of programmed cell death - PubMed, accessed October 25, 2025, https://pubmed.ncbi.nlm.nih.gov/19066471/
24. Taurolidine | Cancer Research - AACR Journals, accessed October 25, 2025, https://aacrjournals.org/cancerres/article/61/18/6816/507760/TaurolidineCytotoxic-and-Mechanistic-Evaluation-of
25. Pharmacokinetics of taurolidine following repeated intravenous ..., accessed October 25, 2025, https://pubmed.ncbi.nlm.nih.gov/17518510/
26. Taurolidine-Heparin: Side Effects, Uses, Dosage, Interactions, Warnings - RxList, accessed October 25, 2025, https://www.rxlist.com/taurolidine-heparin/generic-drug.htm
27. Taurolidine heparin: uses, dosing, warnings, adverse events, interactions - MedCentral, accessed October 25, 2025, https://www.medcentral.com/drugs/monograph/187824-323102/taurolidine-in-heparin-sodium-porcine-intra-catheter
28. FDA approval for DefenCath (taurolidine and heparin) catheter lock solution to reduce the incidence of catheter-related bloodstream infections - CorMedix - Medical Update Online, accessed October 25, 2025, https://medicalupdateonline.com/2023/11/fda-approval-for-defencath-taurolidine-and-heparin-catheter-lock-solution-to-reduce-the-incidence-of-catheter-related-bloodstream-infections-cormedix/
29. Taurolidine/Heparin Lock Solution and Catheter-Related ..., accessed October 25, 2025, https://pubmed.ncbi.nlm.nih.gov/37678222/
30. FDA approves new drug under special pathway for patients receiving hemodialysis, accessed October 25, 2025, https://www.fda.gov/drugs/news-events-human-drugs/fda-approves-new-drug-under-special-pathway-patients-receiving-hemodialysis
31. Taurolidine and Catheter-related Bloodstream Infection: A Systematic Review of the Literature | Semantic Scholar, accessed October 25, 2025, https://www.semanticscholar.org/paper/bb7c0d025aa1347cfd14425abddb17d70aabb828
32. Taurolidine lock solution for catheter-related bloodstream infections in pediatric patients: A meta-analysis - PMC - PubMed Central, accessed October 25, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC7138323/
33. Antimicrobial Lock Solutions as a Method to Prevent Central Line–Associated Bloodstream Infections: A Meta-analysis of Randomized Controlled Trials - Oxford Academic, accessed October 25, 2025, https://academic.oup.com/cid/article/59/12/1741/2895316
34. Taurolidine lock reduces recurrent catheter-related bloodstream infections in patients with chronic intestinal failure: A randomized, placebo-controlled trial in a real-world clinical setting - PubMed, accessed October 25, 2025, https://pubmed.ncbi.nlm.nih.gov/40554263/
35. Postmarketing experience with Neutrolin® (taurolidine, heparin, calcium citrate) catheter lock solution in hemodialysis patients - PubMed Central, accessed October 25, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC5978892/
36. Taurolidine lock in the treatment of colonization and infection of totally implanted venous access devices in cancer patients - PubMed, accessed October 25, 2025, https://pubmed.ncbi.nlm.nih.gov/34148394/
37. (PDF) The Use of Taurolidine as an Adjunctive Treatment to Reduce Recurrent Peritonitis in Peritoneal Dialysis Patients - ResearchGate, accessed October 25, 2025, https://www.researchgate.net/publication/394878322_The_Use_of_Taurolidine_as_an_Adjunctive_Treatment_to_Reduce_Recurrent_Peritonitis_in_Peritoneal_Dialysis_Patients
38. The Use of Taurolidine as an Adjunctive Treatment to Reduce Recurrent Peritonitis in Peritoneal Dialysis Patients - PubMed, accessed October 25, 2025, https://pubmed.ncbi.nlm.nih.gov/40988813/
39. The Use of Taurolidine as an Adjunctive Treatment to Reduce ..., accessed October 25, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC12451647/
40. Taurolidine Peritoneal Dialysis Catheter Lock to Treat Relapsing Peritoneal Dialysis Peritonitis - PMC - PubMed Central, accessed October 25, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC7568065/
41. Taurolidine as adjuvant treatment of relapsing peritonitis in peritoneal dialysis patients, accessed October 25, 2025, https://www.revistanefrologia.com/en-taurolidine-as-adjuvant-treatment-relapsing-articulo-S2013251420300328
42. Unsuccessful application of taurolidine in the treatment of fungal peritonitis in peritoneal dialysis - ResearchGate, accessed October 25, 2025, https://www.researchgate.net/publication/49700984_Unsuccessful_application_of_taurolidine_in_the_treatment_of_fungal_peritonitis_in_peritoneal_dialysis
43. Taurolidine Lock Solutions for the Prevention of Catheter-Related Bloodstream Infections: A Systematic Review and Meta-Analysis of Randomized Controlled Trials | PLOS One - Research journals, accessed October 25, 2025, https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0079417
44. (PDF) The best solution down the line: an observational study on ..., accessed October 25, 2025, https://www.researchgate.net/publication/354561978_The_best_solution_down_the_line_an_observational_study_on_taurolidine-_versus_citrate-based_lock_solutions_for_central_venous_catheters_in_hemodialysis_patients
45. The best solution down the line: an observational study on taurolidine- versus citrate-based lock solutions for central venous catheters in hemodialysis patients - PubMed, accessed October 25, 2025, https://pubmed.ncbi.nlm.nih.gov/34517829/
46. Mechanical Complications in Central Lines Using Taurolidine vs Ethanol Lock Therapy in Children with Intestinal Failure - PubMed, accessed October 25, 2025, https://pubmed.ncbi.nlm.nih.gov/35213858/
47. Mechanical Complications in Central Lines Using Taurolidine Versus Ethanol Lock Therapy in Children With Intestinal Failure - Ovid, accessed October 25, 2025, https://www.ovid.com/journals/jpga/pdf/10.1097/mpg.0000000000003434~mechanical-complications-in-central-lines-using-taurolidine
48. An Alternative to Ethanol Locks (Not Available in U.S.) - gutsandgrowth, accessed October 25, 2025, https://gutsandgrowth.com/2022/07/05/an-alternative-to-ethanol-locks-not-available-in-u-s/
49. The effect of taurolidine on brain tumor cells - PubMed, accessed October 25, 2025, https://pubmed.ncbi.nlm.nih.gov/12014655/
50. Exploring the potential of taurolidine in inducing mobilization and detachment of colon cancer cells: a preliminary in-vitro study - ProQuest, accessed October 25, 2025, https://search.proquest.com/openview/3670e950ce65ff18edf41dc101672ab1/1?pq-origsite=gscholar&cbl=2028884
51. (PDF) Exploring the potential of taurolidine in inducing mobilization and detachment of colon cancer cells: a preliminary in-vitro study - ResearchGate, accessed October 25, 2025, https://www.researchgate.net/publication/361265375_Exploring_the_potential_of_taurolidine_in_inducing_mobilization_and_detachment_of_colon_cancer_cells_a_preliminary_in-vitro_study
52. Treatment of Glioblastoma with Intravenous Taurolidine. First Clinical Experience - Anticancer Research, accessed October 25, 2025, https://ar.iiarjournals.org/content/anticanres/24/2C/1143.full-text.pdf
53. Treatment of Glioblastoma with Intravenous Taurolidine. First Clinical Experience, accessed October 25, 2025, https://www.researchgate.net/publication/8550997_Treatment_of_Glioblastoma_with_Intravenous_Taurolidine_First_Clinical_Experience
54. Treatment of glioblastoma with intravenous taurolidine. First clinical experience - PubMed, accessed October 25, 2025, https://pubmed.ncbi.nlm.nih.gov/15154639/
55. Taurolidine in Treating Patients With Recurrent or Progressive Glioma - Meghan M Johnson Memorial Scholarship Fund - Clinical Trial Finder, accessed October 25, 2025, https://meghan-johnson-scholarship-fund.clinicaltrialconnect.com/trials/NCT00022360
56. Taurolidine-Fibrin-Sealant-Matrix Using Spray Application for Local Treatment of Brain Tumors - ResearchGate, accessed October 25, 2025, https://www.researchgate.net/publication/8545436_Taurolidine-Fibrin-Sealant-Matrix_Using_Spray_Application_for_Local_Treatment_of_Brain_Tumors
57. Taurolidine reduces the tumor stimulating cytokine interleukin-1beta in patients with resectable gastrointestinal cancer: a multicentre prospective randomized trial - PMC - PubMed Central, accessed October 25, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC2667516/
58. (PDF) Taurolidine reduces the tumor stimulating cytokine interleukin-1beta in patients with resectable gastrointestinal cancer: A multicentre prospective randomized trial - ResearchGate, accessed October 25, 2025, https://www.researchgate.net/publication/24222682_Taurolidine_reduces_the_tumor_stimulating_cytokine_interleukin-1beta_in_patients_with_resectable_gastrointestinal_cancer_A_multicentre_prospective_randomized_trial
59. Taurolidine reduces the tumor stimulating cytokine interleukin-1beta in patients with resectable gastrointestinal cancer: a multicentre prospective randomized trial - PubMed, accessed October 25, 2025, https://pubmed.ncbi.nlm.nih.gov/19309495/
60. RandomiSed clinical trial assessing Use of an anti-inflammatoRy aGent in attenUating peri-operatiVe inflAmmatioN in non-meTastatic colon cancer - PubMed Central, accessed October 25, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC6091184/
61. Search for 2008-005570-12 - Clinical Trials register, accessed October 25, 2025, https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-005570-12
62. Taurolidine-related adverse events in patients on home parenteral nutrition frequently indicate catheter-related problems | Request PDF - ResearchGate, accessed October 25, 2025, https://www.researchgate.net/publication/362377098_Taurolidine-related_adverse_events_in_patients_on_home_parenteral_nutrition_frequently_indicate_catheter-related_problems?_tp=eyJjb250ZXh0Ijp7InBhZ2UiOiJzY2llbnRpZmljQ29udHJpYnV0aW9ucyIsInByZXZpb3VzUGFnZSI6bnVsbCwic3ViUGFnZSI6bnVsbH19
63. Taurolidine-related adverse events in patients on home parenteral nutrition frequently indicate catheter-related problems - PubMed, accessed October 25, 2025, https://pubmed.ncbi.nlm.nih.gov/36067590/
64. DefenCath (Taurolidine and Heparin Catheter Lock Solution): Side ..., accessed October 25, 2025, https://www.rxlist.com/defencath-drug.htm
65. DEFENCATH (taurolidine and heparin) - This label may not be the latest approved by FDA. For current labeling information, please visit https://www.fda.gov/drugsatfda, accessed October 25, 2025, https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/214520s000lbl.pdf
66. DefenCath Taurolidine and Heparin CLS | Official Website for HCPs, accessed October 25, 2025, https://www.defencath.com/
67. Taurolidine and heparin (route not applicable) - Side effects & uses - Mayo Clinic, accessed October 25, 2025, https://www.mayoclinic.org/drugs-supplements/taurolidine-and-heparin-route-not-applicable/description/drg-20560880
68. Taurolidine / Sodium citrate / Heparin 100 units Monograph ..., accessed October 25, 2025, https://pch.health.wa.gov.au/-/media/Files/Hospitals/PCH/General-documents/Health-professionals/ChAMP-Monographs/Taurolidine-Sodium-Citrate.pdf
69. Anti-Biofilm Anti-Occlusion Anti-Infection - TauroLock, accessed October 25, 2025, https://taurolock.tauropharm.com/media/downloads/open-access/promotional-material/taurolock-triple-efficacy-brochure.pdf
70. www.sec.gov, accessed October 25, 2025, https://www.sec.gov/Archives/edgar/data/1410098/000121390021026113/R7.htm
71. CorMedix Gains CE Mark for Neutrolin Catheter Lock Solution - BioSpace, accessed October 25, 2025, https://www.biospace.com/cormedix-gains-ce-mark-for-neutrolin-catheter-lock-solution
72. taurolock-u25000-ifu-en.pdf - TauroPharm, accessed October 25, 2025, https://taurolock.tauropharm.com/media/downloads/open-access/ifus/taurolock-u25000-ifu-en.pdf
73. A. Description and Specifications TauroLock™ is a catheter lock solution indicated for patients who use a port or a silicone o, accessed October 25, 2025, https://taurolock.tauropharm.com/media/downloads/open-access/ifus/taurolock-ifu-en.pdf
74. FAQ about our lock solutions | TauroLock™ - TauroPharm, accessed October 25, 2025, https://taurolock.tauropharm.com/en/faq
75. Tauropharm Australia Pty Ltd - Taurolock HEP 500 - Non-antibiotic-based antimicrobial catheter lock solution (272680) | Therapeutic Goods Administration (TGA), accessed October 25, 2025, https://www.tga.gov.au/resources/artg/272680
76. Tauropharm Australia Pty Ltd | Therapeutic Goods Administration (TGA), accessed October 25, 2025, https://www.tga.gov.au/resources/sponsor/tauropharm-australia-pty-ltd
77. Taurolidine 1.35% and 4% Citrate (Taurolock) NIM, accessed October 25, 2025, https://resources.schn.health.nsw.gov.au/policies/policies/pdf/2020-151.pdf